Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)

PHASE3WithdrawnINTERVENTIONAL

Timeline

Start Date

May 31, 2021

Primary Completion Date

June 21, 2021

Study Completion Date

May 31, 2025

Conditions

Age-related Macular Degeneration (AMD)

Interventions

DRUG

brolucizumab

Pre-filled Syringes for intravitreal injection